Matthew N Jaffa1, Jamie E Podell1, Madeleine C Smith1, Arshom Foroutan1, Adam Kardon1, Wan-Tsu W Chang1, Melissa Motta1, Gunjan Y Parikh1, Kevin N Sheth1, Neeraj Badjatia1, Michael J Armahizer1, J Marc Simard1, Nicholas A Morris2. 1. From the Departments of Neurology (M.N.J., J.E.P., A.K., W.-T.W.C., M.M., G.Y.P., N.B., N.A.M.), Emergency Medicine (W.-T.W.C.), Pharmacy Services (M.J.A.), Neurosurgery (J.M.S.), Pathology (J.M.S.), and Physiology (J.M.S.), and Program in Trauma, R. Adams Cowley Shock Trauma Center (M.N.J., J.E.P., W.-T.W.C., M.M., G.Y.P., N.B., N.A.M.), University of Maryland School of Medicine (M.C.S., A.F., A.K.), Baltimore; and Department of Neurology, Division of Neurocritical Care and Emergency Neurology (K.N.S.), Yale School of Medicine, New Haven, CT. 2. From the Departments of Neurology (M.N.J., J.E.P., A.K., W.-T.W.C., M.M., G.Y.P., N.B., N.A.M.), Emergency Medicine (W.-T.W.C.), Pharmacy Services (M.J.A.), Neurosurgery (J.M.S.), Pathology (J.M.S.), and Physiology (J.M.S.), and Program in Trauma, R. Adams Cowley Shock Trauma Center (M.N.J., J.E.P., W.-T.W.C., M.M., G.Y.P., N.B., N.A.M.), University of Maryland School of Medicine (M.C.S., A.F., A.K.), Baltimore; and Department of Neurology, Division of Neurocritical Care and Emergency Neurology (K.N.S.), Yale School of Medicine, New Haven, CT. nicholas.morris@som.umaryland.edu.
Abstract
OBJECTIVE: Little is known about the prevalence of continued opioid use following aneurysmal subarachnoid hemorrhage (aSAH) despite guidelines recommending their use during the acute phase of disease. We sought to determine prevalence of opioid use following aSAH and test the hypothesis that acute pain and higher inpatient opioid dose increased outpatient opioid use. METHODS: We reviewed consecutively admitted patients with aSAH from November 2015 through September 2019. We retrospectively collected pain scores and daily doses of analgesics. Pain burden was calculated as area under the pain-time curve. Univariate and multivariable regression models determined risk factors for continued opioid use at discharge and outpatient follow-up. RESULTS: We identified 234 patients with aSAH with outpatient follow-up. Continued opioid use was common at discharge (55% of patients) and follow-up (47% of patients, median 63 [interquartile range 49-96] days from admission). Pain burden, craniotomy, and racial or ethnic minority status were associated with discharge opioid prescription in multivariable analysis. At outpatient follow-up, pain burden (odds ratio [OR] 1.88, 95% confidence interval [CI] 1.5-2.4), depression (OR 3.1, 95% CI 1.1-8.8), and racial or ethnic minority status (OR 2.1, 95% CI 1.1-4.0) were independently associated with continued opioid use; inpatient opioid dose was not. CONCLUSION: Continued opioid use following aSAH is prevalent and related to refractory pain during acute illness, but not inpatient opioid dose. More efficacious analgesic strategies are needed to reduce continued opioid use in patients following aSAH. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that continued opioid use following aSAH is associated with refractory pain during acute illness but not hospital opioid exposure.
OBJECTIVE: Little is known about the prevalence of continued opioid use following aneurysmal subarachnoid hemorrhage (aSAH) despite guidelines recommending their use during the acute phase of disease. We sought to determine prevalence of opioid use following aSAH and test the hypothesis that acute pain and higher inpatient opioid dose increased outpatient opioid use. METHODS: We reviewed consecutively admitted patients with aSAH from November 2015 through September 2019. We retrospectively collected pain scores and daily doses of analgesics. Pain burden was calculated as area under the pain-time curve. Univariate and multivariable regression models determined risk factors for continued opioid use at discharge and outpatient follow-up. RESULTS: We identified 234 patients with aSAH with outpatient follow-up. Continued opioid use was common at discharge (55% of patients) and follow-up (47% of patients, median 63 [interquartile range 49-96] days from admission). Pain burden, craniotomy, and racial or ethnic minority status were associated with discharge opioid prescription in multivariable analysis. At outpatient follow-up, pain burden (odds ratio [OR] 1.88, 95% confidence interval [CI] 1.5-2.4), depression (OR 3.1, 95% CI 1.1-8.8), and racial or ethnic minority status (OR 2.1, 95% CI 1.1-4.0) were independently associated with continued opioid use; inpatient opioid dose was not. CONCLUSION: Continued opioid use following aSAH is prevalent and related to refractory pain during acute illness, but not inpatient opioid dose. More efficacious analgesic strategies are needed to reduce continued opioid use in patients following aSAH. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that continued opioid use following aSAH is associated with refractory pain during acute illness but not hospital opioid exposure.
Authors: Maxime Thibault; François Girard; Robert Moumdjian; Philippe Chouinard; Daniel Boudreault; Monique Ruel Journal: Can J Anaesth Date: 2007-07 Impact factor: 5.063
Authors: E Yvette Hilario; Margaret L Griffin; R Kathryn McHugh; Katherine A McDermott; Hilary S Connery; Garrett M Fitzmaurice; Roger D Weiss Journal: J Subst Abuse Treat Date: 2014-07-18
Authors: Serena L Orr; Benjamin W Friedman; Suzanne Christie; Mia T Minen; Cynthia Bamford; Nancy E Kelley; Deborah Tepper Journal: Headache Date: 2016-06 Impact factor: 5.887
Authors: Rachel Sayko Adams; Cindy Parks Thomas; Grant A Ritter; Sue Lee; Mayada Saadoun; Thomas V Williams; Mary Jo Larson Journal: Mil Med Date: 2019-01-01 Impact factor: 1.437
Authors: Adam Kardon; Robert S Murray; Mazhar Khalid; Luana Colloca; J Marc Simard; Neeraj Badjatia; Sarah B Murthi; Nicholas A Morris Journal: Neurohospitalist Date: 2022-05-12
Authors: Ryan B Felix; Aniruddha Rao; Mazhar Khalid; Yang Wang; Luana Colloca; Sarah B Murthi; Nicholas A Morris Journal: BMJ Open Date: 2021-11-30 Impact factor: 2.692
Authors: Matthew N Jaffa; Ruchira M Jha; Jonathan Elmer; Adam Kardon; Jamie E Podell; Benjamin E Zusman; Madeleine C Smith; J Marc Simard; Gunjan Y Parikh; Michael J Armahizer; Neeraj Badjatia; Nicholas A Morris Journal: Neurocrit Care Date: 2021-06-09 Impact factor: 3.210